These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28095170)

  • 1. Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications.
    Shen C; Zhao B; Liu L; Shih YT
    J Oncol Pract; 2017 Feb; 13(2):e152-e162. PubMed ID: 28095170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries.
    Shih YT; Xu Y; Liu L; Smieliauskas F
    J Clin Oncol; 2017 Aug; 35(22):2482-2489. PubMed ID: 28471711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
    Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
    Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer.
    Li M; Liao K; Pan IW; Shih YT
    JCO Oncol Pract; 2022 Nov; 18(11):e1739-e1749. PubMed ID: 36099549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
    Doshi JA; Li P; Huo H; Pettit AR; Kumar R; Weiss BM; Huntington SF
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s78-86. PubMed ID: 27270157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
    Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
    Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
    Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
    Shen C; Zhao B; Liu L; Shih YT
    Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Out-of-pocket costs and oral cancer medication discontinuation in the elderly.
    Kaisaeng N; Harpe SE; Carroll NV
    J Manag Care Spec Pharm; 2014 Jul; 20(7):669-75. PubMed ID: 24967520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
    Dusetzina SB; Keating NL
    J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
    Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
    J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic Myelogenous Leukemia.
    Talon B; Calip GS; Lee TA; Sharp LK; Patel P; Touchette DR
    JCO Oncol Pract; 2021 Nov; 17(11):e1811-e1820. PubMed ID: 33961496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
    Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
    Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-gap discounts in Medicare Part D and specialty drug use.
    Jung J; Xu WY; Cheong C
    Am J Manag Care; 2017 Sep; 23(9):553-559. PubMed ID: 29087157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
    Patel UD; Davis MM
    J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
    Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
    Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
    Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
    J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.